NTRK1 and neoplasm: Receptor tyrosine kinases (RTKs) are key mediators of tumor cell survival, proliferation, and migratory pathways [1,2], and inhibitors of RTKs have demonstrated anti-tumor efficacy in both the preclinical and clinical settings [3,4].